A study published in Clinical Rheumatology evaluated changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA), finding golimumab resulted in early and sustained improvements.
The study assessed patients who were randomized to IV golimumab 2 mg/kg (n=241) at weeks 0, 4, then every 8 weeks (q8w) through week 52 or placebo (n=239) at weeks 0, 4, then q8w, with crossover to IV golimumab 2 mg/kg at weeks 24, 28, then q8w through Week 52. Additionally, changes from baseline in EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily productivity VAS, and the Work Limitations Questionnaire (WLQ) were also examined. Also evaluated were the relationships between these outcomes and disease activity and patient functional capability post hoc.
The study reported that at week 8, change from baseline in EQ-5D-5L index (0.14 vs 0.04), EQ-VAS (17.16 vs 3.69), daily productivity VAS (-2.91 vs -0.71), and WLQ productivity loss score (-2.92 vs -0.78) was greater in the golimumab group vs the placebo group. Furthermore, at week 52, change from baseline was similar in the golimumab and placebo-crossover groups (EQ-5D-5L index: 0.17 and 0.15; EQ-VAS: 21.61 and 20.84; daily productivity VAS: -2.89 and -3.31; WLQ productivity loss: -4.49 and -3.28, respectively). In continued association, HRQoL and productivity were generally associated with disease activity and functional capability from Week 8 through week 52.
The study concluded that, per the results, IV golimumab resulted in early and sustained improvements in HRQoL and productivity from week 8 through 1 year in patients with PsA. Also, HRQoL and productivity advancements were associated with improvements in disease activity and patient functional capability outcomes. —Jessica Garlewicz
Ogdie A, Walsh JA, Chakravarty SD, et al. The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clin Rheumatol. Published online March 2, 2021;10.1007/s10067-021-05639-1. doi:10.1007/s10067-021-05639-1